About Us
Neurala Biosciences is advancing a new generation of precision-targeted neuromedicines, botanically inspired and pharmaceutically optimised to transform the treatment of psychiatric, neurological, and addictive disorders. Our products range from sub-perceptual (non-psychedelic) to high-dose psychedelic medicines, which act as 'neuroperceptogens' driving insight-led changes in perception, self-understanding, and functional mental health.
Our Story
Neurala Biosciences was founded in 2022 with a bold vision: to advance a new class of botanically inspired, pharmaceutically optimised neuromedicines for psychiatric, neurological, and addictive disorders.
Our origins lie in a decade of pioneering research on DMT and harmala alkaloid therapeutics, including leading the world’s largest study investigating the therapeutic profile and safety of ayahuasca.
Building on this foundation, we achieved a major milestone in 2023 with the successful completion of the world’s first Phase 1 clinical study of a pharmaceutical DMT-harmala formulation, manufactured to precise specifications, demonstrating robust effects and good safety profile.
Our innovative pipeline spans both psychedelic and non-psychedelic medicines, offering precise therapeutic options for complex neuropsychiatric conditions. With multiple patents submitted, a clear regulatory pathway, VC-backed investment, and non-dilutive government funding, we are positioned at the forefront of a revolution in mental health treatment.
Neurala is also proudly associated with the not-for-profit Psychae Institute, which holds foundational equity in the company. Psychae Institute contributes towards reciprocity and culturally informed approaches to botanically-inspired medicines development.
.webp)
Our Progress
We have established a robust foundation for success with patented methods for manufacturing pharmaceutical-grade DMT and harmala alkaloids, through both synthetic production and botanical extraction pathways. Developed in collaboration with CSIRO and IDT Australia, this dual approach ensures supply chain resilience, scalability, and multiple regulatory and commercial options.
Our scientific platform has delivered key product development and clinical milestones since our founding in 2022. We have completed preclinical studies, established GMP manufacturing capabilities, developed therapeutic formulations across multiple product types, and completed a Phase 1 clinical trial. Alongside this, we secured $4.5 million in venture funding and A$550,000 in non-dilutive grants.
With multiple patents filed and a growing intellectual property portfolio, supported by eminent partners including the University of Melbourne and Tin Alley Ventures, we are strongly positioned to advance our mission.
Core Team
%20(2).png)
Our Partners
Our Investors
Investors
Careers
Innovation. Impact. Transformation.
